Ann E. Haig

TL;DR: This study shows that treatment with mepolizumab, an agent designed to target eosinophils, can result in corticosteroid-sparing for patients negative for FIP1L1-PDGFRA who have the hypereos inophilic syndrome.

TL;DR: Mepolizumab was well tolerated and effective as a long-term corticosteroid-sparing agent in PDGFRA-negative HES, and the frequency of adverse events was the primary end point.

TL;DR: In a double-blind study, 385 hypertensive patients stabilized on an angiotensin converting enzyme inhibitor were treated with nabumetone, celecoxib, ibuprofen, or placebo for 4 weeks, causing significantly greater increases in systolic and diastolic blood pressures compared to placebo.

TL;DR: Two large-scale, robust studies demonstrated that rosiglitazone is not active in psoriasis and showed that for a large proportion of subjects receiving placebo, the expectation of a successful treatment, the favorable adverse effect profile of the drug, and the supportive environment of a clinical study conferred beneficial effects.

TL;DR: Nabumetone 30 mg/kg/day (up to 2000 mg/day) demonstrated a safe profile with no loss of efficacy compared to previous treatment in children with JRA.